Skip to main content
Article thumbnail
Location of Repository

Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study

By Lisa F Potts, Alex C Cambon, Owen A Ross, Rosa Rademakers, Dennis W Dickson, Ryan J Uitti, Zbigniew K Wszolek, Shesh N Rai, Matthew J Farrer, David W Hein and Irene Litvan
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3344705
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2003). [Genotoxicity and activation of organophosphate and carbamate pesticides by cytochrome P450 2D6]. Giornaleitaliano di medicina del lavoroedergonomia
    2. (1979). A Simple Sequentially Refective Multiple Test Procedure.
    3. (2007). A: The role of NAT2 gene polymorphism in aetiology of the most frequent neurodegenerative diseases with dementia. Neurologia i neurochirurgiapolska
    4. (2012). Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics
    5. (2011). al: Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet
    6. (1999). Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet
    7. (2010). Association of polymorphism
    8. (2004). Bandmann O: Slow N-acetyltransferase 2 status leads to enhanced intrastriatal dopamine depletion in 6-hydroxydopamine-lesioned rats. ExpNeurol
    9. (2006). CYP450, genetics and Parkinson’s disease: gene × environment interactions hold the key.
    10. (2003). DW: Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. MovDisord
    11. (2001). DW: Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration.
    12. et al: A case-control study of Parkinson’s disease and tobacco use: gene-tobacco interactions.
    13. (1999). et al: A study of five candidate genes in Parkinson’s disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology
    14. (2005). et al: Acetylcholinesterase/ paraoxonase interactions increase the risk of insecticide-induced Parkinson’s disease.
    15. et al: Association of the MAPT locus with Parkinson’s disease.
    16. (2007). et al: Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes? Brain
    17. (2007). et al: High-throughput oncogene mutation profiling in human cancer. Nat Genet
    18. (1999). et al: The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the diseaseassociated H1 haplotype in Italian cases. NeurosciLett
    19. (2005). Fakis G: Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug metabolism reviews
    20. (2006). Farrer LA: Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum Mol Genet
    21. (2003). Furlong CE, et al: Paraoxonase 1 promoter and coding region polymorphisms in Parkinson’s disease.
    22. (2002). Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson’s disease. MovDisord
    23. (2005). gene polymorphism and slow acetylator phenotype with young onset and late onset Parkinson’s disease among Indians. Pharmacogenet Genomics
    24. (2004). gene polymorphisms and susceptibility to Alzheimer’s disease: identification of a novel NAT1 allelic variant.
    25. (2002). Hein DW: Rapid genotype method to distinguish frequent and/ or functional polymorphisms in human N-acetyltransferase-1. Anal Biochem
    26. (2009). Hoglinger GU: In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy. J Cereb Blood Flow Metab
    27. (2007). JC: Association study of the paraoxonase 1 gene with the risk of developing Alzheimer’s disease. Neurobiol Aging
    28. (2004). JH: N-Acetyltransferase 2 gene polymorphism in a group of senile dementia patients in Shanghai suburb. ActaPharmacol Sin
    29. (2011). Juyal RC: Leads from xenobiotic metabolism genes for Parkinson’s disease among north Indians. Pharmacogenet Genomics
    30. (2007). Kostic VS: Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson’s disease. Vojnosanit Pregl
    31. (2001). KP: Suggestions for presenting the results of data analyses.
    32. (1997). LeCouteur DG: The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson’s disease: a case-control study and meta-analysis.
    33. (1994). Litvan I: Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology
    34. (2004). Lombes A, et al: Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe.
    35. (2001). Lovestone S: The microtubule associated protein Tau gene and Alzheimer’s disease- an association study and meta-analysis. NeurosciLett
    36. (2001). Lum-Jones A, et al: Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev
    37. (2007). Mitsumoto H: Identification of a novel D109Y mutation in Cu/Zn superoxide dismutase (sod1) gene associated with amyotrophic lateral sclerosis.
    38. (2007). Mutation of superoxide dismutase elevates reactive species: comparison of nitration and oxidation of proteins in different brain regions of transgenic mice with amyotrophic lateral sclerosis. Neuroscience
    39. (2006). N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene
    40. (1999). Nacetyltransferase (NAT2) genotype and susceptibility of sporadic Alzheimer’s disease. Pharmacogenetics
    41. (1999). NW: Toxins, genetics, and Parkinson’s disease: the role of N-acetyltransferase 2. AdvNeurol
    42. (2005). Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. The Journal of biological chemistry
    43. (2007). Parkin, DJ-1 and mitochondrial dysfunction in Parkinson’s disease. CurrOpinNeurobiol
    44. (2007). PE: Arylamine Nacetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2. Chem Res Toxicol
    45. (2005). Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson’s disease. ActaNeurol Taiwan
    46. (2008). PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. BiochemBiophys Res Commun
    47. (2006). Reamon-Buettner SM: N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson’s disease.
    48. (2000). Rocca WA: Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson’s disease. MovDisord
    49. (2003). SL: Supranuclear gaze palsy and opsoclonus after Diazinon poisoning.
    50. (2007). SW: Mutant SOD1-induced neuronal toxicity is mediated by increased mitochondrial superoxide levels.
    51. (2004). Tzourio C: CYP2D6 polymorphism, pesticide exposure, and Parkinson’s disease. Ann Neurol

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.